Journal of Cellular and Molecular Medicine · 2020 · 81 citations · 24 references
MedicineOncologyPharmacologyApoptosisCarcinogenesisMolecular OncologyApoptosis In CancerCancer Cell SignalingEpithelial-mesenchymal TransitionEpithelial-to-mesenchymal TransitionLung CancerLung Cancer PharmacotherapyCancer Cell Proliferation InhibitionEpithelial-mesenchymal Transition In CancerFocal Adhesion ComplexesFocal Adhesion Kinase SignalingSmall Cell Lung Cancer TherapySmall Cell Lung Cancer TreatmentTraditional Chinese MedicineVimentin Expression
Small cell lung cancer (SCLC) is a severe malignant with high morbidity; however, few effective and secure therapeutic strategy is used in current clinical practice. Oridonin is a small molecule from the traditional Chinese herb Rabdosia rubescens. This study mainly aimed to investigate the role of oridonin on inhibiting the process of H1688, a kind of small cell lung cancer cells from human. Oridonin could suppress H1688 cell proliferation and induce their apoptosis in a high dosage treatment (20 μmol/L). Meanwhile, cell migration was suppressed by oridonin (5 and 10 μmol/L) that did not affect cell proliferation and apoptosis. The expression level of E-cadherin was significantly increased, and the expression of vimentin, snail and slug was reduced after administration of oridonin. These expression changes were associated with the suppressed integrin β1, phosphorylation of focal adhesion kinase (FAK) and ERK1/2. In addition, oridonin (5 and 10 mg/kg) inhibited tumour growth in a nude mouse model; however, HE staining revealed a certain degree of cytotoxicity in hepatic tissue after treatment oridonin (10 mg/kg). Furthermore, the concentration of alanine aminotransferase (ALP) was significantly increased and lactate dehydrogenase (LDH) was reduced after oridonin treatment (10 mg/kg). Immunohistochemical analysis further revealed that oridonin increased E-cadherin expression and reduced vimentin and phospho-FAK levels in vivo. These findings indicated that oridonin can inhibit the migration and epithelial-to-mesenchymal transition (EMT) of SCLC cells by suppressing the FAK-ERK1/2 signalling pathway. Thus, oridonin may be a new drug candidate to offer an effect of anti-SCLC with relative safety.
24
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2018 · 17K citations · Full text
Vimentin on the move: new developments in cell migration
Rachel A. Battaglia, Samed Delic, Harald Herrmann et al. · F1000Research · 2018 · 283 citations · Full text
Masanobu Tsubaki, Makiko Komai, Shinichiro Fujimoto et al. · Journal of Experimental & Clinical Cancer Research · 2013 · 108 citations · Full text
Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway
Ying Lü, Yang Sun, Jianwei Zhu et al. · Cell Death and Disease · 2018 · 101 citations · Full text